ANG Lifesciences India share news, announcements and annual reports
BSE: 540694Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 2 Nov 2026. Previous close ₹32.09.
2 Nov: open ₹32.09, high ₹34.50, low ₹31.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43 Cr3,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.81
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −22.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −6.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.47
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,769
ANG Lifesciences India share news and announcements
374 announcements, routine notices left out, newest first. Page 6 of 8.
Apr 2021
14 Apr · Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Mar 2021
Feb 2021
Jan 2021
22 Jan · Announcement Under Reg. 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Purchase Of A Running Unit
6 Jan · Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 01 Jan · Results
Dec 2020
31 Dec · Meeting
12 Dec · Reg. 34 (1) Annual Report
Nov 2020
12 Nov · Results
6 Nov · Board meeting
Meeting on 12 Nov 2020: half yearly results
Oct 2020
26 Oct · Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligation And Disclosure) Requirement, 2015 For The Half Year Ended 30Th September, 2020
26 Oct · Compliance Certificate For The Half Year Ended 30 September, 2020
23 Oct · Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 022 Oct · Shareholding for the Period Ended September 30, 2020
Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click ....
Sep 2020
Jul 2020
21 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 021 Jul · Results
21 Jul · Board meeting
1 Jul · Board meeting
Meeting on 21 Jul 2020: half yearly results and audited results
Jun 2020
29 Jun · Board meeting
May 2020
27 May · PCS Certificate Under Regulation 40(10) For The Half Year Ended 31-03-2020
26 May · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....